BeiGene Company Insiders

BGNE Stock  USD 153.94  2.59  1.65%   
BeiGene's insiders are aggressively selling. The analysis of the overall insider sentiment regarding BeiGene suggests that all insiders are panicking. BeiGene employs about 10.6 K people. The company is managed by 29 executives with a total tenure of roughly 148 years, averaging almost 5.0 years of service per executive, having 365.52 employees per reported executive.
Xiaodong Wang  Chairman
Chairman CoFounder
John Oyler  Chairman
Chairman of the Board, CEO, Founder

BeiGene's Insider Buying Vs Selling

0

 
Selling
 
Buying

Latest Trades

2024-04-10John OylerDisposed 26716 @ 148.89View
2024-03-12John OylerDisposed 37668 @ 164.02View
2024-02-29Julia Aijun WangDisposed 397 @ 167.08View
2023-07-31Chan Henry LeeDisposed 791 @ 216.26View
2023-07-12Daniel S. GoldmanDisposed @ 192.06
2023-07-10Daniel S. GoldmanDisposed @ 192.53
2023-07-03Julia Aijun WangDisposed 472 @ 179.55View
2023-06-26Xiaobin WuDisposed 1495 @ 182.37View
2023-06-23Julia Aijun WangDisposed 840 @ 182.85View
2023-06-20Lai WangDisposed 1325 @ 192.42View
2023-06-14Advisors Ltd. HhlrDisposed 273728 @ 207.72View
2023-06-12Advisors Ltd. HhlrDisposed 1250212 @ 195.21View
2023-06-08Advisors Ltd. HhlrDisposed 1163825 @ 218.14View
2023-06-07Xiaobin WuDisposed 3291 @ 224.73View
2023-05-08Xiaobin WuDisposed 7000 @ 253.72View
Monitoring BeiGene's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BeiGene. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade BeiGene Stock refer to our How to Trade BeiGene Stock guide.

BeiGene's Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with BeiGene's future performance. Based on our forecasts, it is anticipated that BeiGene will maintain a workforce of about 10600 employees by June 2024.
 
Yuan Drop
 
Covid

BeiGene's latest congressional trading

Congressional trading in companies like BeiGene, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in BeiGene by those in governmental positions are based on the same information available to the general public.
2023-07-12Representative Daniel GoldmanAcquired Under $15KVerify
2020-11-13Representative Greg GianforteAcquired Under $15KVerify

BeiGene Management Team Effectiveness

The company has return on total asset (ROA) of (0.124) % which means that it has lost $0.124 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2226) %, meaning that it created substantial loss on money invested by shareholders. BeiGene's management efficiency ratios could be used to measure how well BeiGene manages its routine affairs as well as how well it operates its assets and liabilities. As of May 1, 2024, Return On Tangible Assets is expected to decline to -0.16. In addition to that, Return On Capital Employed is expected to decline to -0.32. At present, BeiGene's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 215.8 M, whereas Non Currrent Assets Other are projected to grow to (17.8 M).
As of May 1, 2024, Common Stock Shares Outstanding is expected to decline to about 72.1 M. The current year's Net Loss is expected to grow to about (1.7 B)

BeiGene Workforce Comparison

BeiGene is number one stock in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 24,056. BeiGene totals roughly 10,600 in number of employees claiming about 44% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.36) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.61) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.61.

BeiGene Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific BeiGene insiders, such as employees or executives, is commonly permitted as long as it does not rely on BeiGene's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, BeiGene insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-03-01
0.0556
1
18
 27,794 
 147,094 
2023-06-01
1.0357
29
28
 4,937,452 
 4,361,788 
2023-03-01
0.0435
1
23
 67,635 
 1,030,922 
2022-09-01
0.0526
2
38
 15,600 
 98,486 
2022-06-01
1.4375
23
16
 9,156,654 
 1,048,091 
2021-12-01
0.1039
8
77
 78,557 
 141,237 
2021-09-01
0.0433
9
208
 207,903 
 1,706,030 
2021-06-01
0.5806
36
62
 2,773,385 
 3,301,137 
2021-03-01
0.1667
5
30
 18,500 
 460,154 
2020-12-01
0.2069
12
58
 3,559,739 
 8,714,572 
2020-09-01
0.076
19
250
 44,610,223 
 1,047,613 
2020-06-01
0.2969
19
64
 4,292,255 
 246,514 
2020-03-01
0.2727
3
11
 24,970 
 47,000 
2019-12-01
0.1525
9
59
 596,650 
 591,773 
2019-09-01
0.3636
8
22
 287,420 
 71,625 
2019-06-01
1.1304
26
23
 6,423,288 
 845,763 
2019-03-01
0.0625
2
32
 35,910 
 69,077 
2018-12-01
0.0864
7
81
 102,000 
 985,746 
2018-09-01
0.1818
2
11
 5,814,100 
 16,679 
2018-06-01
13.0
26
2
 7,104,073 
 5,000,000 
2018-03-01
0.1064
5
47
 2,025,198 
 944,865 
2017-12-01
0.0714
3
42
 9,602 
 491,501 
2017-09-01
0.375
6
16
 2,786,056 
 454,077 
2017-06-01
0.8
12
15
 6,596,420 
 220,981 
2016-12-01
6.0
6
1
 7,203,925 
 93,750 
2016-09-01
0.5833
7
12
 5,510,000 
 442,310 
2016-03-01
0.8846
23
26
 213,902,954 
 135,561,007 

BeiGene Notable Stakeholders

A BeiGene stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as BeiGene often face trade-offs trying to please all of them. BeiGene's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting BeiGene's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Xiaodong WangChairman CoFounderProfile
John OylerChairman of the Board, CEO, FounderProfile
Jason YangSenior Vice President Head of Clinical DevelopmentProfile
Wendy YanSenior Vice President Head of Regulatory AffairsProfile
Xiaobin WuPresident COOProfile
Howard LiangCFO and Chief Strategy OfficerProfile
Thomas MalleyNon-Executive Independent DirectorProfile
Qingqing YiDirectorProfile
Timothy ChenDirectorProfile
Ke TangDirectorProfile
Ranjeev KrishanaDirectorProfile
Donald GlazerDirectorProfile
Michael GollerDirectorProfile
JingShyh SuIndependent DirectorProfile
Titus BallVP OfficerProfile
Chan LeeGeneral VPProfile
Mi ZhouDirector RelationsProfile
Liza HeapesHead RelationsProfile
Wang LaiGlobal RDProfile
Eric HedrickInterim Chief Medical Officer, Immuno-OncologyProfile
Julia WangCFO OfficerProfile
Hing ChauCompany SecretaryProfile
Daniel MallerVP AccountingProfile
Kevin MannixVP RelationsProfile
Jason RadfordSenior DevelopmentProfile
Yang JiChief OfficerProfile
Diana FrancisVP ComplianceProfile
Yan QiSenior ChinaProfile
Jane HuangChief Medical Officer, HematologyProfile

About BeiGene Management Performance

The success or failure of an entity such as BeiGene often depends on how effective the management is. BeiGene management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of BeiGene management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the BeiGene management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.15)(0.16)
Return On Capital Employed(0.30)(0.32)
Return On Assets(0.15)(0.16)
Return On Equity(0.25)(0.26)
The data published in BeiGene's official financial statements usually reflect BeiGene's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of BeiGene. For example, before you start analyzing numbers published by BeiGene accountants, it's critical to develop an understanding of what BeiGene's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of BeiGene's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, BeiGene's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in BeiGene's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of BeiGene. Please utilize our Beneish M Score to check the likelihood of BeiGene's management manipulating its earnings.

BeiGene Workforce Analysis

Traditionally, organizations such as BeiGene use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare BeiGene within its industry.

BeiGene Manpower Efficiency

Return on BeiGene Manpower

Revenue Per Employee232K
Revenue Per Executive84.8M
Net Loss Per Employee83.2K
Net Loss Per Executive30.4M
Working Capital Per Employee225.8K
Working Capital Per Executive82.5M
When determining whether BeiGene is a strong investment it is important to analyze BeiGene's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact BeiGene's future performance. For an informed investment choice regarding BeiGene Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BeiGene. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade BeiGene Stock refer to our How to Trade BeiGene Stock guide.
You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.

Complementary Tools for BeiGene Stock analysis

When running BeiGene's price analysis, check to measure BeiGene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BeiGene is operating at the current time. Most of BeiGene's value examination focuses on studying past and present price action to predict the probability of BeiGene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BeiGene's price. Additionally, you may evaluate how the addition of BeiGene to your portfolios can decrease your overall portfolio volatility.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Is BeiGene's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BeiGene. If investors know BeiGene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BeiGene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(8.45)
Revenue Per Share
23.554
Quarterly Revenue Growth
0.669
Return On Assets
(0.12)
Return On Equity
(0.22)
The market value of BeiGene is measured differently than its book value, which is the value of BeiGene that is recorded on the company's balance sheet. Investors also form their own opinion of BeiGene's value that differs from its market value or its book value, called intrinsic value, which is BeiGene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BeiGene's market value can be influenced by many factors that don't directly affect BeiGene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BeiGene's value and its price as these two are different measures arrived at by different means. Investors typically determine if BeiGene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BeiGene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.